Galectin Therapeutics 3Q 2026: EPS ($0.04) — 10-Q Summary
Galectin Therapeutics (GALT) reported no revenue for Q3 2026, with a net loss of $3.57M, improved from $8.22M YoY. EPS loss narrowed to $0.04 from $0.13. R&D costs fell 40% due to reduced activity. The company has $11.7M in cash and expects funding through June 2027. It filed a Phase 3 protocol with the FDA and is exploring partnerships.
How this was made

The 30-second read
Why it matters
The filing provides the first public numbers for the quarter, highlighting cost reductions and cash runway through mid‑2027.
Market read
Micro‑cap biotech earnings with modest loss improvement; limited immediate trading impact.
What to watch
Potential upcoming FDA decision on belapectin could be a larger catalyst than current earnings.
Background
Galectin Therapeutics filed its Q3 2026 10‑Q, reporting no revenue and a narrowed net loss.
Ticker impact
10-Q shows net loss narrowed to $3.57M and EPS loss to $0.04, new quarterly financials.
slight pressure as investors weigh loss against narrowing trend
Micro‑cap biotech with no revenue; loss reduction is positive but magnitude is small, likely limited price move.
Market effects
Biotech sector may see modest confidence boost from loss narrowing but no broader impact.
US biotech micro‑caps could see slight uptick.
Limited to investors tracking small‑cap biotech earnings.
Counterpoint
Despite loss narrowing, continued cash burn and no product revenue suggest caution.
Key entities
- companyGalectin Therapeutics Inc.
US‑listed biotech developing belapectin.